Skip to main content
About Us
Board
Careers
News, Events & Blog
Annual Report
Contact Us
Physicians
Insights
Clinical Trials
Relationship Opportunities
Physician Careers
Learn More
Patients
Resources
About Clinical Trials
Find a Clinical Trial
Practice Success
Practice Growth & Advocacy
Practice Management
Public Policy
Payer Strategy
Clinical Innovation
Precision Medicine
Clinical Research
Patient-Centric Care
Value-Based Care
Surgery
Radiation and Imaging
Clinical Services and Nursing
Submit
Home
>
Network News
>
UroToday: ASCO 2018 – Pembrolizumab Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial
UroToday: ASCO 2018 – Pembrolizumab Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer: 2-Year Follow-Up from KEYNOTE-045 Trial
About Us
Board
Careers
News, Events & Blog
Annual Report
Contact Us
Physicians
Insights
Clinical Trials
Relationship Opportunities
Physician Careers
Learn More
Patients
Resources
About Clinical Trials
Find a Clinical Trial
Practice Success
Practice Growth & Advocacy
Practice Management
Public Policy
Payer Strategy
Clinical Innovation
Precision Medicine
Clinical Research
Patient-Centric Care
Value-Based Care
Surgery
Radiation and Imaging
Clinical Services and Nursing